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URINARY/KIDNEY DISEASES/DISORDERS—
Economic Outcomes Presentations
PUK3
COST EFFECTIVENESS OF INTENSIVE
BEHAVIORAL MANAGEMENT VERSUS DDAVP
IN PRIMARY NOCTURNAL ENURESIS
Egan TF1, McGhan WF2
1Kennedy Health System and the University of Sciences in
Philadelphia, Stratford, NJ, USA; 2Philadelphia College of
Pharmacy, Philadelphia, PA, USA
Primary Nocturnal Enuresis (PNE), or nighttime bedwet-
ting, is the second most common chronic ailment in child-
hood. Fifteen to 20% of 5 year-olds wet at least monthly.
It has been estimated that up to 10% of children with
PNE will remain enuretic throughout their lifetime if
untreated.
OBJECTIVE: This model was developed to determine the
cost effectiveness of therapies for PNE.
METHODS: A decision tree model was developed on
software designed by Treeage Software Inc. to access 
the cost-effective treatment of PNE. The model assumed
6 months of initial treatment for 100 patients in each
group. If the initial treatment failed or the patient
relapsed, they were retreated with an alternative therapy.
Probabilities used in the model to determine patient
responses, relapses, and complication rates were obtained
from published clinical trials. The model includes direct
cost including drug acquisition, physician consultation,
intensive behavioral management (IBM), relapses, and
complications. Probabilities and direct cost data for vaso-
pressin (DDAVP), IBM, minor or serious adverse events
(AE), and relapses were included in the model. Indirect
cost included cost of disposable and nondisposable
diapers, excess wear on bedclothes and sheets, washing
and drying and the caregiver’s time. The cost of these
assumed 5 wet nights per week. Effectiveness was deter-
mined when there was a signiﬁcant increase in dry patient
nights.
RESULTS: The cost effectiveness ratio (total cost effec-
tiveness) for IBM is $14,607 versus $17,608 and $19,644
respectively for IBM, oral and inhaled DDAVP for a com-
plete treatment cycle. One-way sensitivity analysis did not
substantially alter the results.
CONCLUSION: The model identiﬁes Intensive Be-
havioral Management as cost effective treatment of Pri-
mary Nocturnal Enuresis.
PUK4
AN ECONOMIC MODEL OF OVERACTIVE
BLADDER IN NORWAY
Bentkover J1, Bachleda M2, Kulseng-Hansen S3, Corey R4,
Kurth H1 
1Innovative Health Solutions, Brookline, MA, USA; 2Pharmacia
Corporation, Peapack, NJ, USA; 3Baerum Sykehus, Gjettum,
Norway; 4University of the Sciences in Philadelphia, Pharmacia
Corporation, Peapack, NJ, USA
OBJECTIVE: An economic model was developed to 
estimate the comparative cost-effectiveness of tolterodine
extended-release and immediate-release for overactive
bladder (OAB) in Norway.
METHODS: The study population included patients
seeking OAB treatment divided into successfully treated
patients (STP), deﬁned by clinical efﬁcacy and adjusted
by annual persistency, and patients failing treatment
(PFT). Direct costs included drugs, incontinence pads,
physician visits, lab tests/diagnostics and associated
comorbidities. Indirect costs included lost productivity,
comprised of missed/reduced work, caregiver time and
reduced activities of daily living. Resource utilization,
productivity losses and cost data were integrated from a
comprehensive literature review, the National Insurance
Administration, national statistics, a telephone survey,
and expert medical panels. A societal perspective was
taken to model a one-year time horizon.
RESULTS: The prevalence of OAB in Norway is esti-
mated to be 17% of people over age 40 in 2001 (approx-
imately 337,000 people or 7.5% of the Norwegian
population), with only 20% of those patients seeking
treatment. STP use fewer pads per day, visit physicians
less frequently, have fewer lab tests/diagnostics, experi-
ence fewer comorbidities, and have smaller productivity
losses than PFT. Cost drivers are productivity losses (STP:
NOK23251 (€2914) vs. PFT: NOK42851 (€5370)) and
pad usage (STP: NOK300 (€38) vs. PFT: NOK1748
(€219)) (average annual costs per patient). Tolterodine
extended-release (TER) had an 18% greater efﬁcacy than
tolterodine immediate-release (TIR) and persistence on
therapy was higher for TER. Therefore, effectiveness was
higher for TER versus TIR. Cost per STP was NOK69586
(€8720) for TER and NOK95530 (€11972) for TIR. 
TER is the dominant treatment strategy in the analysis,
with an incremental cost-effectiveness of—NOK16416 
(-€2057).
CONCLUSION: Tolterodine extended-release is a more
cost-effective treatment than tolterodine immediate-
release in treating OAB as measured by cost per success-
fully treated patient in Norway.
PUK5
INCIDENCE AND COST ASSOCIATED WITH
PHARMACOLOGICAL TREATMENT FOR
EMPLOYEES DIAGNOSED WITH URINARY AND
OVERACTIVE BLADDER DISORDERS
Muchmore L1,Williamson TE2, Gardner H1
1Options and Choices, Cheyenne, WY, USA; 2Pharmacia,
Peapack, NJ, USA
OBJECTIVES: Urinary antispasmodics (UA) are the most
common group of pharmaceuticals in the treatment of
urinary and overactive bladder disorders (OAB). This
study compares a population of employees diagnosed
with OAB and actively seeking a pharmacological treat-
ment regimen to those who are not seeking such treat-
ment. A large, multi-employer database was used to 
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study the cumulative incidence of pharmacological treat-
ment regimens, beneﬁts utilization, and cost differences
between the treatment and non-treatment groups.
METHODS: Examining a database of 78,655 employees
with complete medical and prescription drug data for a
four-year period, this study includes the 1,944 employees
who had clinical diagnoses of OAB (ICD9 codes 595, 
596 and 788). Treatment incidence and health beneﬁts
utilization is reported for this population.
RESULTS: 15.7% of the employee population examined
were actively seeking pharmaceutical treatment for OAB.
Employees seeking treatment were more likely to be older
(p < .001), female (p < .01), and non-union (*p < .07).
Employees with a dependent diagnosed with OAB
incurred ($1,170) in additional annual beneﬁts cost after
controlling for demographic and OAB severity variables
(p < .02). Employees diagnosed with OAB used 62%
fewer co-morbid medical services (74% less cost) after
initial treatment. After controlling for other factors,
employees in the treatment group were found to have
lower annual STD beneﬁts cost ($554) (p < .04) and lower
total annual costs ($248) (*p < .82).
CONCLUSIONS: One in every six OAB-diagnosed
employees examined actively sought pharmaceutical
treatment. Employees who are care-givers for dependents
with OAB use signiﬁcantly more health-related beneﬁts
on an annual basis than employees without such respon-
sibilities. Post-treatment employees experience a reduc-
tion in the use of co-morbid medical services and
OAB-related medical services. OAB treatment may rep-
resent a “ripple-effect” beneﬁt to employers by reducing
total beneﬁts cost. Further research about OAB treat-
ment beneﬁts for employers and employees over time is
appropriate.
PUK6
A BUDGET IMPACT ANALYSIS OF EARLY
REFERRAL TO A NEPHROLOGIST FOR ELDERLY
MEDICARE PATIENTS WITH END-STAGE RENAL
DISEASE
Shih YCT1, Guo AM2, Prasad M1, Just PM2
1MEDTAP International Inc, Bethesda, MD, USA; 2Baxter
Healthcare Corporation, Deerﬁeld, IL, USA
End-stage renal disease (ESRD) patients referred to a
nephrologist at least 4 months before initiation of renal
replacement therapy (RRT) (“early referral”; ER) were
found to have better survival than those referred at a later
stage (“late referral”; LR). However, ER may result in
earlier utilization of medical resources, which is a greater
ﬁnancial burden on Medicare.
OBJECTIVES: To examine the budget impact of ER for
elderly Medicare ESRD beneﬁciaries.
METHODS: The decision model considered Medicare
beneﬁciaries aged 65 and above in their ﬁrst year of
ESRD. The preliminary model included an incident
cohort at 6 months prior to RRT initiation and followed
them for one year. It was expanded to a Markov model
for longer timeframes with a 3% discount rate. ER and
LR differed by three parameters: survival advantage asso-
ciated with early initiation of dialysis; higher likelihood
of selecting peritoneal dialysis for ER; and higher costs of
initial dialysis for LR. Base case values were obtained
from the literature. RRT modalities included center
hemodialysis (HD), home HD, CAPD/CCPD, other 
dialysis, and transplantations. Transition probabilities,
survival, and costs associated with each modality were
obtained from the United State Renal Data System 
aggregate data.
RESULTS: For the base case scenario, ER was cost-saving
for Medicare, especially for ﬁrst-year ESRD beneﬁciaries.
One-year analysis suggested a 10% increase in ER would
reduce the Medicare budget by $2,541 per ESRD beneﬁ-
ciary. The reduction became $2,159 and $1,801 over 3-
and 5-year periods, respectively, as the survival advantage
of ER translated into longer maintenance dialysis dura-
tions. A larger reduction could be realized if more bene-
ﬁciaries were referred earlier. Sensitivity analysis indicated
the ﬁndings of budget reduction were robust.
CONCLUSIONS: Early referral to nephrologists may
reduce Medicare’s budget.
URINARY/KIDNEY DISEASES/DISORDERS—
Quality of Life Presentations
PUK7
DEVELOPMENT OF THE SYMPTOM
FREQUENCY AND BOTHERSOMENESS SCALE
FOR STRESS URINARY INCONTINENCE 
(SFB-SUI)
Garvart S1, Bowman L2, Buesching D2, Patrick D3, Martin M4
1Eli Lilly and Company, Windlesham, UK; 2Eli Lilly and
Company, Indianapolis, IN, USA; 3University of Washington,
Seattle, WA, USA; 4Health Research Associates, Seattle, WA,
USA
OBJECTIVES: The Symptom Frequency and Bother-
someness (SFB) scale measures the frequency and bother-
someness of patient symptoms associated with urge
urinary incontinence, mixed stress and urge urinary
incontinence, and painful irritable bladder syndromes.
The SFB has demonstrated good psychometric perfor-
mance in mixed urinary incontinence. The objective of
this study was to modify the original SFB instrument to
measure symptom frequency and bothersomeness for
stress urinary incontinence symptoms (SUI).
METHODS: The SFB was revised to address symptoms
speciﬁc to SUI based on a review of current literature,
data from a previous pilot study, and consultation with a
urologist. The Revised Version of the instrument (SFB-
SUI) was piloted with eight patients diagnosed with pure
SUI. Cognitive Debrieﬁng was conduced to (1) assess the
relevance and importance of the items to patients with
SUI; (2) identify issues in formatting, language, or clarity;
(3) assess construct validity; and (4) identify gaps in key
content areas.
